<DOC>
	<DOCNO>NCT01463397</DOCNO>
	<brief_summary>Primary Objective : To assess efficacy SAR292833 versus placebo reduce pain intensity associate chronic peripheral neuropathic pain use 11-point numerical rating scale ( NRS ) . Secondary Objectives : - To compare effect SAR292833 placebo change neuropathic pain symptom versus baseline Neuropathic Pain Symptoms Inventory ( NPSI ) ; - To evaluate effect SAR292833 comparison placebo change pain intensity mechanical allodynia ; - To investigate safety tolerability SAR292833 comparison placebo ; - To investigate pharmacokinetics ( PK ) relationships main efficacy parameter pharmacodynamic effect ( PD ) pharmacokinetics ( PK/PD ) SAR292833 patient chronic peripheral neuropathic pain .</brief_summary>
	<brief_title>Efficacy Safety SAR292833 Administration 4 Weeks Patients With Chronic Peripheral Neuropathic Pain</brief_title>
	<detailed_description>Total study duration ( screen last follow-up visit ) 9 week include 3 week follow-up period .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<criteria>Inclusion criterion : The study include adult patient either gender , 18 85 age , sign informed consent form , present chronic peripheral neuropathic pain associate : diabetic polyneuropathy , postherpetic neuralgia . The neuropathic pain must distinct neuroanatomically plausible distribution sensory sign symptom confirm DN4 ( Douleur Neuropathique en 4 question ) score ≥4 present 3 month . SAR292833 take fed condition . Therefore , patient judge reliable fulfill condition ( use breakfast dinner ) include study . Exclusion criterion : Patients baseline average daily pain intensity neuropathic pain &lt; 5 11point NRS last 7 day randomization ; Patients pain intensity ≥ 9 11point NRS Visit 1 ; Any pain neuropathic pain equal great severity ; Sensory polyneuropathy post chemotherapy context cancer AIDS ; Patients complex regional pain syndrome ; Trigeminal neuralgia ; Patients clinically significant uncontrolled hepatic , metabolic , gastrointestinal , cardiovascular , respiratory , neurological ( neuropathy ) , psychiatric , hematological , renal , dermatological disease , medical condition might interfere evaluation study medication accord Investigator 's medical judgment ; Patients statins metabolized CYP3A4 , ( e.g . simvastatin , atorvastatin ) abnormal CPK level ; Major depression ; Serum creatinine &gt; 150 μmol/L ; ALT 3 x ULN ; Total bilirubin &gt; 1.5 x ULN except know Gilbert syndrome ; Presence sign clinically significant abnormality standard electrocardiogram ( ECG ) record screen visit accord Investigator 's medical judgment ; Pregnant breastfeed woman ; Women childbearing potential ( WOCBP ) , protect highly effective contraceptive method birth control ; Patients diabetes mellitus time diagnosis diabetes enrolment &lt; 6 month ; Patients diabetes mellitus HbA1c &gt; 10 % fast plasma glucose &gt; 250 mg/dL ; Use follow drug within 7 day prior start pain intensity assessment ( Visit 2 ) : Antidepressants ( except stable [ &gt; 30 day ] regimen Selective serotonin reuptake inhibitor ( SSRIs ) treatment anxiety depression ) , anticonvulsant mexiletine treatment pain ; Opioids morphinomimetics ; Fatty acid supplement , primrose oil , myoinositol , chromium picolinate know used neuropathic pain ; Acetyl salicylic acid ( ASA ) except 325 mg/d myocardial infarction transient ischemic attack prophylaxis ; Benzodiazepines indicate low dos sleep disorder ; Capsaicin patch ; Lidocaine patch ; Electroconvulsive therapy within 30 day baseline evaluation ; CYP3A4 potent moderate inhibitor ; CYP3A4 potent moderate inducer ; Substrates CYP3A4 narrow therapeutic window . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>